Regeneron's EYLEA HD met key goals in the Phase 3 QUASAR trial for macular edema after retinal vein occlusion, with FDA ...

With Eylea biosimilar competition creeping in and Roche’s Vabsymo jockeying for market share in key indications, Regeneron is ...

The high-dose version of Regeneron's eye treatment Eylea hit its primary endpoint in a late-stage study for macular edema ...

The Phase III win could help Regeneron and Bayer expand into retinal vein occlusion, a move that the partners need to help ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN), a biotechnology company, announced on Tuesday that its phase III QUASAR trial evaluating Eylea HD for the treatment of patients with macular ...

Results from a trial comparing three treatments for serious eye disease have shown that Regeneron and Bayer's Eylea is the most effective. The trial was sponsored by the US government-funded ...

equivalent to around 17 letters on a standard eye chart. Roche's drug was also comparable to Eylea on achieving drying of retinal fluid from baseline, measured by reduction in central subfield ...

Lead drug Eylea has global sales approaching $10 billion annually and is approved for wet age-related macular degeneration and other eye-related indications. The drug remains well positioned ...

Regeneron Pharmaceuticals REGN announced that it has met the primary endpoint in a late-stage study evaluating Eylea HD (aflibercept) Injection 8 mg to treat patients with macular edema following ...

The intended patient population includes those with central, branch and hemiretinal vein occlusions. Eylea is Regeneron’s blockbuster eye disease drug, which is already approved for wet age-related ...